Of note, lerociclib demonstrated a superior efficacy compared to palbociclib and did not induce severe neutropenia in an estrogen receptor positive breast cancer dog animal model, which is a common side effect of CDK4/6 inhibitors. This evidence concerns the gene CDK4 and neutropenia.